

6. LITERATUR

6 Literaturverzeichnis

- Almawi WY, Abou Jaoude MM and Li XC (2002) Transcriptional and post-transcriptional mechanisms of glucocorticoid antiproliferative effects. *Hematol Oncol* **20**(1):17-32.
- Amsterdam A and Sasson R (2002) The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. *Mol Cell Endocrinol* **189**(1-2):1-9.
- Artik S and Ruzicka T (2003) Complementary therapy for atopic eczema and other allergic skin diseases. *Dermatol Ther* **16**(2):150-163.
- Azuma H, Horie S, Muto S, Otsuki Y, Matsumoto K, Morimoto J, Gotoh R, Okuyama A, Suzuki S, Katsuoka Y and Takahara S (2003) Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. *Anticancer Res* **23**(4):3183-3193.
- Bamberger CM, Bamberger AM, de Castro M and Chrousos GP (1995) Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. *J Clin Invest* **95**(6):2435-2441.
- Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. *Clin Sci (Lond)* **94**(6):557-572.
- Barnes PJ and Adcock IM (2003) How do corticosteroids work in asthma? *Ann Intern Med* **139**(5 Pt 1):359-370.
- Baudhuin LM, Jiang Y, Zaslavsky A, Ishii I, Chun J and Xu Y (2004) S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). *Faseb J* **18**(2):341-343.
- Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE and Foster ML (2001) Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. *J Immunol* **166**(3):1975-1982.
- Braem C, Blaschke T, Panek-Minkin G, Herrmann W, Schlupp P, Paepenmuller T, Muller-Goyman C, Mehnert W, Bittl R, Schafer-Korting M and Kramer KD (2007) Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. *J Control Release* **119**(1):128-135.
- Brazzini B and Pimpinelli N (2002) New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. *Am J Clin Dermatol* **3**(1):47-58.
- Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M and Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. *J Biol Chem* **277**(24):21453-21457.
- Buttgereit F (2000) Mechanisms and clinical relevance of nongenomic glucocorticoid actions. *Z Rheumatol* **59 Suppl 2**:II/119-123.
- Chae HJ, Chae SW, Kang JS, Bang BG, Cho SB, Park RK, So HS, Kim YK, Kim HM and Kim HR (2000) Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide. *Endocrinology* **141**(8):2904-2913.
- Charman C and Williams H (2003) The use of corticosteroids and corticosteroid phobia in atopic dermatitis. *Clin Dermatol* **21**(3):193-200.
- Cross SE, Magnusson BM, Winckle G, Anissimov Y and Roberts MS (2003) Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers. *J Invest Dermatol* **120**(5):759-764.

6. LITERATURVERZEICHNIS

- Croxtall JD, Paul-Clark M and Van Hal PT (2003) Differential modulation of glucocorticoid action by FK506 in A549 cells. *Biochem J* **376**(Pt 1):285-290.
- Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW and Flower RJ (2002) Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. *Br J Pharmacol* **135**(2):511-519.
- Cutroneo KR (2002) Relationship between glucocorticoid-mediated early decrease of protein synthesis and the steady state decreases of glucocorticoid receptor and TGF-beta activator protein. *Int J Biochem Cell Biol* **34**(2):194-203.
- Cutroneo KR (2003) How is Type I procollagen synthesis regulated at the gene level during tissue fibrosis. *J Cell Biochem* **90**(1):1-5.
- Cuvillier O and Levade T (2001) Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. *Blood* **98**(9):2828-2836.
- De Bosscher K, Vanden Berghe W and Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. *Endocr Rev* **24**(4):488-522.
- Distelhorst CW (2002) Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. *Cell Death Differ* **9**(1):6-19.
- Evans-Storms RB and Cidlowski JA (2000) Delineation of an antiapoptotic action of glucocorticoids in hepatoma cells: the role of nuclear factor-kappaB. *Endocrinology* **141**(5):1854-1862.
- Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL and Henson PM (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. *J Immunol* **148**(7):2207-2216.
- Falkenstein E, Tillmann HC, Christ M, Feuring M and Wehling M (2000) Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. *Pharmacol Rev* **52**(4):513-556.
- Fesq H, Lehmann J, Kontny A, Erdmann I, Theiling K, Rother M, Ring J, Cevc G and Abeck D (2003) Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. *Br J Dermatol* **149**(3):611-619.
- Franklin RA and McCubrey JA (2000) Kinases: positive and negative regulators of apoptosis. *Leukemia* **14**(12):2019-2034.
- Gottlicher M, Heck S and Herrlich P (1998) Transcriptional cross-talk, the second mode of steroid hormone receptor action. *J Mol Med* **76**(7):480-489.
- Grey A, Chen Q, Callon K, Xu X, Reid IR and Cornish J (2002) The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase. *Endocrinology* **143**(12):4755-4763.
- Groves RW, Giri J, Sims J, Dower SK and Kupper TS (1995) Inducible expression of type 2 IL-1 receptors by cultured human keratinocytes. Implications for IL-1-mediated processes in epidermis. *J Immunol* **154**(8):4065-4072.
- Gysler A, Konigsmann U and Schäfer-Korting M (1999) [Tridimensional skin models recording percutaneous absorption]. *Altex* **16**(2):67-72.
- Gysler A, Lange K, Kortting HC and Schafer-Korting M (1997) Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. *Pharm Res* **14**(6):793-797.
- Hammer S, Sauer B, Spika I, Schraut C, Kleuser B and Schafer-Korting M (2004) Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. *J Cell Biochem* **91**(4):840-851.

6. LITERATURVERZEICHNIS

- Hammer S, Spika I, Sippl W, Jessen G, Kleuser B, Holtje HD and Schafer-Korting M (2003) Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants. *Steroids* **68**(4):329-339.
- Hanifin J, Abrams B., Cherill, R. (1994) Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a nonhalogenated prednisolone derivate. *J Geriatr Dermatol* **(2)**:119-127.
- Hatz HJ (1998) Glucocorticoide. *Wissenschaftliche Verlagsgesellschaft, Stuttgart*.
- Hein R, Korting HC and Mehring T (1994) Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. *Skin Pharmacol* **7**(5):300-306.
- Heng MC, Heng HL and Allen SG (1990) Basement membrane changes in psoriatic patients on long-term topical corticosteroid therapy. *Clin Exp Dermatol* **15**(2):83-90.
- Hong Y, Hu FQ and Yuan H (2006) Effect of PEG2000 on drug delivery characterization from solid lipid nanoparticles. *Pharmazie* **61**(4):312-315.
- Huwiler A and Pfeilschifter J (2006) Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy. *Curr Pharm Des* **12**(35):4625-4635.
- Isoyama N, Takai K, Tsuchida M, Matsumura M and Naito K (2006) Evidence that FTY720 induces rat thymocyte apoptosis. *Transpl Immunol* **15**(4):265-271.
- Jenning V (1999) Feste Lipid-Nanopartikel (SLNTM) als Trägersysteme für die dermale Applikation von Retinol: Wirkstoffinkorporation, -freisetzung und Struktur. *Dissertation Freie Universität Berlin*.
- Jenning V, Gysler A, Schäfer-Korting M and Gohla SH (2000) Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. *Eur J Pharm Biopharm* **49**(3):211-218.
- Jores K, Haberland A, Wartewig S, Mader K and Mehnert W (2005) Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. *Pharm Res* **22**(11):1887-1897.
- Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C and Mäder K (2004) Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. *J Control Release* **95**(2):217-227.
- Kalariya M, Padhi BK, Chougule M and Misra A (2005) Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications. *Indian J Exp Biol* **43**(3):233-240.
- Kang YC, Kim KM, Lee KS, Namkoong S, Lee SJ, Han JA, Jeoung D, Ha KS, Kwon YG and Kim YM (2004) Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. *Cell Death Differ* **11**(12):1287-1298.
- Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH, Schäfer-Korting M and Kleuser B (2007) Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. *Am J Pathol* **170**(1):281-292.
- Koivukangas V, Karvonen J, Risteli J and Oikarinen A (1995) Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. *Br J Dermatol* **132**(1):66-68.
- Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J and Nietsch KH (2002) Different skin thinning potential of equipotent medium-strength glucocorticoids. *Skin Pharmacol Appl Skin Physiol* **15**(2):85-91.
- Kremer FaS, A. (2002) Broadband dielectric spectroscopy. *Springer, Berlin*:35-56.

- Kupper TS and Groves RW (1995) The interleukin-1 axis and cutaneous inflammation. *J Invest Dermatol* **105**(1 Suppl):62S-66S.
- Kurucz I, Toth S, Nemeth K, Torok K, Csillik-Perczel V, Pataki A, Salamon C, Nagy Z, Szekely JI, Horvath K and Bodor N (2003) Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). *J Pharmacol Exp Ther* **307**(1):83-92.
- Lange K, Gysler A, Bader M, Kleuser B, Korting HC and Schäfer-Kortting M (1997) Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. *Pharm Res* **14**(12):1744-1749.
- Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC and Schäfer-Kortting M (2000) Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. *Skin Pharmacol Appl Skin Physiol* **13**(2):93-103.
- Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R and Fan ST (2004) FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. *Carcinogenesis* **25**(12):2397-2405.
- Lehmann P, Zheng P, Lavker RM and Kligman AM (1983) Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. *J Invest Dermatol* **81**(2):169-176.
- Leone FT, Fish JE, Szeffler SJ and West SL (2003) Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. *Chest* **124**(6):2329-2340.
- Lombardi-Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Roder B, Kramer KD and Schäfer-Kortting M (2005) Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. *J Control Release* **110**(1):151-163.
- Maceyka M, Payne SG, Milstien S and Spiegel S (2002) Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. *Biochim Biophys Acta* **1585**(2-3):193-201.
- Maia CS, Mehnert W and Schäfer-Kortting M (2000) Solid lipid nanoparticles as drug carriers for topical glucocorticoids. *Int J Pharm* **196**(2):165-167.
- Manggau M, Kim DS, Ruwisch L, Vogler R, Korting HC, Schafer-Kortting M and Kleuser B (2001) 1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. *J Invest Dermatol* **117**(5):1241-1249.
- Maruyama K, Kashihara N, Yamasaki Y, Sato M, Sugiyama H, Okamoto K, Maeshima Y, Odawara M, Sasaki J and Makino H (2001) Methylprednisolone accelerates the resolution of glomerulonephritis by sensitizing mesangial cells to apoptosis. *Exp Nephrol* **9**(5):317-326.
- Maskarinec SA, Hannig J, Lee RC and Lee KY (2002) Direct observation of poloxamer 188 insertion into lipid monolayers. *Biophys J* **82**(3):1453-1459.
- Means CK, Xiao CY, Li Z, Zhang T, Omens JH, Ishii I, Chun J and Brown JH (2007) Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol*.
- Mehnert W and Mäder K (2001) Solid lipid nanoparticles: production, characterization and applications. *Adv Drug Deliv Rev* **47**(2-3):165-196.
- Messmer UK, Winkel G, Briner VA and Pfeilschifter J (1999) Glucocorticoids potently block tumour necrosis factor-alpha- and lipopolysaccharide-induced apoptotic cell death in

6. LITERATURVERZEICHNIS

- bovine glomerular endothelial cells upstream of caspase 3 activation. *Br J Pharmacol* **127**(7):1633-1640.
- Moran TJ, Gray S, Mikosz CA and Conzen SD (2000) The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. *Cancer Res* **60**(4):867-872.
- Müller RH, Mader K and Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. *Eur J Pharm Biopharm* **50**(1):161-177.
- Müller RH, Radtke M and Wissing SA (2002) Nanostructured lipid matrices for improved microencapsulation of drugs. *Int J Pharm* **242**(1-2):121-128.
- Muller RH, Radtke M and Wissing SA (2002) Nanostructured lipid matrices for improved microencapsulation of drugs. *Int J Pharm* **242**(1-2):121-128.
- Murphy JE, Robert C and Kupper TS (2000) Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. *J Invest Dermatol* **114**(3):602-608.
- Natoli G, Costanzo A, Guido F, Moretti F, Bernardo A, Burgio VL, Agresti C and Levrero M (1998) Nuclear factor kB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2. *J Biol Chem* **273**(47):31262-31272.
- Ng KT, Man K, Ho JW, Sun CK, Lee TK, Zhao Y, Lo CM, Poon RT and Fan ST (2007) Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. *Int J Oncol* **30**(2):375-380.
- Nguyen CA, Allemann E, Schwach G, Doelker E and Gurny R (2003) Cell interaction studies of PLA-MePEG nanoparticles. *Int J Pharm* **254**(1):69-72.
- Niedner R (1991) Principles of rational therapy with external glucocorticosteroids. *Hautarzt* **42**(5):337-346.
- Niedner R (2003) Topical corticosteroids versus topical inhibitors of calcineurin. *Hautarzt* **54**(4):338-341.
- Oakley RH, Sar M and Cidlowski JA (1996) The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. *J Biol Chem* **271**(16):9550-9559.
- Oikarinen A and Autio P (1991) New aspects of the mechanism of corticosteroid-induced dermal atrophy. *Clin Exp Dermatol* **16**(6):416-419.
- Oikarinen A, Autio P, Vuori J, Vaananen K, Risteli L, Kiistala U and Risteli J (1992) Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. *Br J Dermatol* **126**(2):172-178.
- Page M, Bejaoui N, Cinq-Mars B and Lemieux P (1988) Optimization of the tetrazolium-based colorimetric assay for the measurement of cell number and cytotoxicity. *Int J Immunopharmacol* **10**(7):785-793.
- Pegi A, Julijana K, Slavko P, Janez S and Marjeta S (2003) The effect of lipophilicity of spin-labeled compounds on their distribution in solid lipid nanoparticle dispersions studied by electron paramagnetic resonance. *J Pharm Sci* **92**(1):58-66.
- Ponec M, De Kloet ER and Kempenaar JA (1980) Corticoids and human skin fibroblasts: intracellular specific binding in relation to growth inhibition. *J Invest Dermatol* **75**(4):293-296.
- Ponec M and Kempenaar JA (1983) Biphasic entry of glucocorticoids into cultured human skin keratinocytes and fibroblasts. *Arch Dermatol Res* **275**(5):334-344.
- Prakash A and Benfield P (1998) Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. *Drugs* **55**(1):145-163.
- Radtke M (2002) Nanostructured lipid carriers (NLC): Untersuchungen zur Struktur, Wirkstoffinkorporation und Stabilität. *Dissertation Freie Universität Berlin*.

6. LITERATURVERZEICHNIS

- Ramalingam A, Hirai A and Thompson EA (1997) Glucocorticoid inhibition of fibroblast proliferation and regulation of the cyclin kinase inhibitor p21Cip1. *Mol Endocrinol* **11**(5):577-586.
- Russell SB, Trupin JS, Kennedy RZ, Russell JD and Davidson JM (1995) Glucocorticoid regulation of elastin synthesis in human fibroblasts: down-regulation in fibroblasts from normal dermis but not from keloids. *J Invest Dermatol* **104**(2):241-245.
- Sanchez T and Hla T (2004) Structural and functional characteristics of S1P receptors. *J Cell Biochem* **92**(5):913-922.
- Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A and Schäfer-Korting M (2002) Drug targeting by solid lipid nanoparticles for dermal use. *J Drug Target* **10**(6):489-495.
- Sauer B, Gonska H, Manggau M, Kim DS, Schraut C, Schafer-Korting M and Kleuser B (2005) Sphingosine 1-phosphate is involved in cytoprotective actions of calcitriol in human fibroblasts and enhances the intracellular Bcl-2/Bax rheostat. *Pharmazie* **60**(4):298-304.
- Schacke H, Rehwinkel H and Asadullah K (2005) Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. *Curr Opin Investig Drugs* **6**(5):503-507.
- Schackert HK, Korting, H.C. and Schäfer-Korting, M. (2000) Qualitative and quantitative Assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo *BioDrugs*(13):267-277.
- Schäfer-Korting M, Korting HC, Kerscher MJ and Lenhard S (1993) Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. *Clin Pharmacol Ther* **54**(4):448-456.
- Schafer-Korting M, Mehnert W and Korting HC (2007) Lipid nanoparticles for improved topical application of drugs for skin diseases. *Adv Drug Deliv Rev*.
- Schäfer-Korting M, Schmid MH and Korting HC (1996) Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. *Drug Saf* **14**(6):375-385.
- Shen Y, Cai M, Xia W, Liu J, Zhang Q, Xie H, Wang C, Wang X and Zheng S (2007) FTY720, a synthetic compound from *Isaria sinclairii*, inhibits proliferation and induces apoptosis in pancreatic cancer cells. *Cancer Lett.*
- Siddiqui AA, Jaffar T, Khan N, Azami R and Waqar MA (1992) Effect of dexamethasone on collagen synthesis in fibroblasts cultured in collagen lattice. *Biochem Soc Trans* **20**(2):207S.
- Sikora E, Rossini GP, Grassilli E, Bellesia E, Salomoni P and Franceschi C (1996) Interference between DNA binding activities of AP-1 and GR transcription factors in rat thymocytes undergoing dexamethasone-induced apoptosis. *Acta Biochim Pol* **43**(4):721-731.
- Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD and Schäfer-Korting M (2004) Glucocorticoid entrapment into lipid carriers--characterisation by parelectric spectroscopy and influence on dermal uptake. *J Control Release* **97**(3):493-502.
- Stecova J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, Seltmann H, Korting HC, Kramer KD and Schäfer-Korting M (2007) Cyproterone Acetate Loading to Lipid Nanoparticles for Topical Acne Treatment: Particle Characterisation and Skin Uptake. *Pharm Res.*
- Sugito K, Koshinaga T, Inoue M, Ikeda T, Hagiwara N, Kusafuka T and Fukuzawa M (2006) Effect of FTY720 in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes in gut-associated lymphoid tissues. *Transplant Proc* **38**(9):3058-3060.
- Valotis A and Hogger P (2004) Significant receptor affinities of metabolites and a degradation product of mometasone furoate. *Respir Res* **5**:7.

6. LITERATURVERZEICHNIS

- van der Burg B and van der Saag PT (1996) Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. *Mol Hum Reprod* **2**(6):433-438.
- Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF and Coenraads PJ (1999) The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. *Br J Dermatol* **140**(6):1114-1121.
- Vayssiére BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H and Resche-Rigon M (1997) Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. *Mol Endocrinol* **11**(9):1245-1255.
- Veien NK, Olholm Larsen P, Thestrup-Pedersen K and Schou G (1999) Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. *Br J Dermatol* **140**(5):882-886.
- Vermeer H, Hendriks-Stegeman BI, van den Brink CE, van der Saag PT, van der Burg B, van Buul-Offers SC and Jansen M (2003) A novel specific bioassay for the determination of glucocorticoid bioavailability in human serum. *Clin Endocrinol (Oxf)* **59**(1):49-55.
- Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. *J Immunol Methods* **184**(1):39-51.
- Webster JC and Cidlowski JA (1999) Mechanisms of Glucocorticoid-receptor-mediated Repression of Gene Expression. *Trends Endocrinol Metab* **10**(10):396-402.
- Yoncheva K, Lizarraga E and Irache JM (2005) Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. *Eur J Pharm Sci* **24**(5):411-419.
- Zhao Y, Man K, Lo CM, Ng KT, Li XL, Sun CK, Lee TK, Dai XW and Fan ST (2004) Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway. *Am J Transplant* **4**(9):1399-1407.
- Zimmermann E and Müller RH (2001) Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. *Eur J Pharm Biopharm* **52**(2):203-210.